ArticleInternational journal of molecular sciences2022
Multi-Omics Immune Interaction Networks in Lung Cancer Tumorigenesis, Proliferation, and Survival.
Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- TheraMind: a multi-LLM ensemble for accelerating drug repurposing in lung cancer via case report mining.NPJ precision oncology · 2026Article
- A machine learning approach for multimodal data fusion for survival prediction in cancer patients.NPJ precision oncology · 2025Article
- Overexpression and clinicopathological significance of zinc finger protein 71 in hepatocellular carcinoma.World journal of hepatology · 2025Article
- Multiomics of Aging and Aging-Related Diseases.International journal of molecular sciences · 2024Review
- Scientific figures interpreted by ChatGPT: strengths in plot recognition and limits in color perception.NPJ precision oncology · 2024Article
- Preclinical Repurposing of Sitagliptin as a Drug Candidate for Colorectal Cancer by TargetingInternational journal of molecular sciences · 2024Article
- Cross-omics strategies and personalised options for lung cancer immunotherapy.Frontiers in immunology · 2024Review
- Bioinformatics Illustrations Decoded by ChatGPT: The Good, The Bad, and The Ugly.bioRxiv : the preprint server for biology · 2023Article
- MicroRNA-Based Discovery of Biomarkers, Therapeutic Targets, and Repositioning Drugs for Breast Cancer.Cells · 2023Article
- Expression-Based Diagnosis, Treatment Selection, and Drug Development for Breast Cancer.International journal of molecular sciences · 2023Article
- MicroRNA, mRNA, and Proteomics Biomarkers and Therapeutic Targets for Improving Lung Cancer Treatment Outcomes.Cancers · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
There are currently no effective biomarkers for prognosis and optimal treatment selection to improve non-small cell lung cancer (NSCLC) survival outcomes. This study further validated a seven-gene panel for diagnosis and prognosis of NSCLC using RNA sequencing and proteomic profiles of patient tumors. Within the seven-gene panel,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.